Here are the 10-K annual reports from Aptevo Therapeutics Inc (APVO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow APVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APVO filings page.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel immunotherapies for cancer using its wholly owned ADAPTIR™ and ADAPTIR-FLEX™ protein platforms. These modular technologies are designed to create monospecific, bispecific and multi-specific antibodies that engage the immune system to selectively attack tumors.
The company’s lead blood cancer candidate, mipletamig (CD123xCD3), has shown clinical activity and a differentiated safety profile in acute myelogenous leukemia, including high remission rates and no cytokine release syndrome to date in a 28‑patient frontline combination set. A Phase 1b/2 RAINIER trial in frontline AML is ongoing, with completion expected in the second half of 2026.
Lead solid tumor candidate ALG.APV-527, partnered with Alligator Bioscience, targets 4‑1BB and 5T4 and produced stable disease in most evaluable Phase 1 patients without severe liver toxicity. Aptevo is also advancing six preclinical ADAPTIR/ADAPTIR-FLEX candidates, including dual and trispecific constructs aimed at difficult solid tumors and validated immune pathways such as PSMA, Nectin‑4, CD40, PD‑L1, 4‑1BB and OX40.